NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the "Company"), a leading medical solutions provider, today announced its financial results for the three months and nine months ended September 30, 2023.
Revenues for the three months ended September 30, 2023 and 2022 were $2,523,193 and $4,932,479, respectively. Revenues for the nine months ended September 30, 2023 and 2022 were $11,278,496 and $10,476,224, respectively. The revenues of the Zhongshan, Qiangsheng, Eurasia, and Minkang hospitals, that are held for sale, were accounted for separately.
Net loss for the three months ended September 30, 2023 and 2022 was $3,134,072 and $3,099,662, respectively, while net loss for the nine months ended September 30, 2023 and 2022 was$1,146,581 and $12, 214,649, respectively.
The Company also reported changes in its cash position and working capital. On September 30, 2023, BIMI had cash of $994,131 and positive working capital of $4,208,695 as compared to cash of $2,336,636 and negative working capital of $326,672 on December 31, 2022.
About BIMI International Medical Inc.
BIMI International Medical Inc. is a healthcare products and services provider, offering a broad range of healthcare products and related services in the U.S. and Asia. For more information, please visit .
Safe Harbor Statement
Certain matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties including, but not limited to, the Company's ability to achieve profitable operations, its ability to continue to operate as a going concern, its ability to continue to meet NASDAQ continued listing requirements, the effects of the spread of COVID-19, the continued market acceptance of the products sold by the recently acquired Phenix Bio subsidiary, general economic conditions and other risk factors detailed in the Company's annual report and other filings with the United States Securities and Exchange Commission.
Investor Relations Contact
Investor Relations Department of BIMI International Medical Inc.
Email: vinson@usbimi.com
Tel: +1 949 981 6274
纽约，2023年12月19日（GLOBE NEWSWIRE）——领先的医疗解决方案提供商必米国际医疗有限公司（以下简称 “公司”）今天公布了截至2023年9月30日的三个月零九个月的财务业绩。
截至2023年9月30日和2022年9月30日的三个月，收入分别为2523,193美元和4,932,479美元。截至2023年9月30日和2022年9月30日的九个月中，收入分别为11,278,496美元和10,476,224美元。待售的中山、强生、欧亚和民康医院的收入分别入账。
截至2023年9月30日和2022年9月30日的三个月，净亏损分别为3,134,072美元和3,099,662美元，而截至2023年9月30日和2022年9月30日的九个月净亏损分别为1,146,581美元和12,214,649美元。
该公司还报告了其现金状况和营运资金的变化。2023年9月30日，BIMI的现金为994,131美元，正营运资金为4,208,695美元，而2022年12月31日的现金为2,336,636美元，负营运资金为326,672美元。
关于 BIMI 国际医疗公司
BIMI International Medical Inc. 是一家医疗保健产品和服务提供商，在美国和亚洲提供广泛的医疗产品和相关服务。欲了解更多信息，请访问。
安全港声明
本新闻稿中讨论的某些事项是前瞻性陈述，涉及许多风险和不确定性，包括但不限于公司实现盈利经营的能力、继续作为持续经营企业的能力、继续满足纳斯达克持续上市要求的能力、COVID-19 利差的影响、市场对最近收购的Phenix所售产品的持续接受生物子公司，公司年度报告和向美国证券交易委员会提交的其他文件中详述的一般经济状况和其他风险因素。
投资者关系联系人
BIMI 国际医疗公司投资者关系部
电子邮件：vinson@usbimi.com
电话：+1 949 981 6274
